Press Release

Haemophilia Treatment Market to Grow with a CAGR of 5.73% through 2029

Increasing prevalence of hemophilia and surging trend of prophylaxis treatment is expected to drive the Global Haemophilia Treatment Market growth in the forecast period, 2025-2029.


According to TechSci Research report, “Haemophilia Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Haemophilia Treatment Market stood at USD 11.34 billion in 2023 and is anticipated to grow with a CAGR of 5.73% in the forecast period, 2025-2029. The increase in research and development studies focused on treatment therapies, along with the growing target population and diagnosis rate, are key factors driving the growth of the hemophilia treatment market.

Additionally, the rise in the use of prophylactic treatment for hemophilia contributes to this growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Haemophilia Treatment Market

The growing global initiatives by government and non-government organizations to raise awareness about hemophilia drugs are key factors driving the market growth. The increasing adoption of prophylactic treatment is also expected to contribute to the demand for hemophilia. Treatment involves regular replacement of clotting factors, and alternative therapies without clotting factors are also being utilized.

The haemophilia market is experiencing growth due to factors such as increased healthcare expenditure, preference for prophylactic treatment, higher diagnosis rates, and significant usage of recombinant coagulation factor. In the near future, recombinant coagulation factor concentrates are projected to dominate the global haemophilia market. Physicians prefer recombinant coagulation factor, which is anticipated to drive the haemophilia market in the forecast period due to its lower risk of bloodborne infection. On the other hand, plasma-derived coagulation factor is expected to have a slower CAGR during the forecast period due to a higher risk of blood-associated infections and limited availability of plasma derived from blood.

The availability of limited treatment therapy options and the increasing responsibility of regulatory authorities to address treatment have led to increased research and development efforts. Both public and commercial healthcare organizations are investing significantly in specialized clinics to meet the specific demands of patients. The number of Hemophilia treatment centers is increasing to provide treatment to underprivileged individuals. Authorities emphasize that individuals with Hemophilia receive treatment at specialized facilities for optimal care and health education. The construction of healthcare centers is expected to fuel the growth of the Hemophilia Market.

One of the primary drivers of haemophilia market growth is the increasing prevalence of haemophilia, which is driving the demand for treatment options. Patients with severe haemophilia require frequent treatment to maintain sufficient clotting factors and prevent bleeding. According to the Centers for Disease Control and Prevention, Hemophilia A affects 1 in every 5,000 male births in the United States. As the number of dependent patients requiring comprehensive care continues to rise, this significant prevalence is expected to have a substantial impact on the market. Moreover, patients receiving quality care are more likely to have fewer co-morbidities and a reduced risk of severe bleeding. Thus, the increasing number of patients with haemophilia has led to a higher demand for haemophilia therapy, resulting in increased product adoption rates.


The Global Haemophilia Treatment Market is segmented into type, product, treatment, therapy, regional distribution, and company.

Based on type, Hemophilia A is projected to maintain a significant market share throughout the forecast period. It is the most prevalent severe bleeding disorder. Replacement therapy, which involves providing the missing coagulation factor, has been the primary treatment approach for both prophylaxis and bleeding management.

According to the data published by the World Federation of Hemophilia in 2021, hemophilia A primarily affects males, accounting for 146,246 cases (88%), followed by females with 5,636 cases (3%), and cases where the sex is unknown, totaling 9,917 (6%). The primary medication used for treating hemophilia A is a concentrated FVIII product, also known as clotting factor. Advances in recombinant protein engineering, gene therapy, and novel strategies targeting the coagulation cascade have enabled the development of recombinant factor products in the laboratory, reducing reliance on human-derived pools of donor-sourced plasma. For example, in December 2021, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The increasing focus on gene therapies for Hemophilia A is expected to drive the growth of this segment.

Based on region, North America segment is expected to grow during the forecast period. Among all regions, North America dominates the market with the largest market share during the forecast period. The initial drivers of regional development include the increasing prevalence and propensity for preventative medicine. In the United States, this condition is often diagnosed early in life. The growth of the hemophilia market in the region is driven by therapeutic advances in hemophilia, leading to the approval of new agents by the Food and Drug Administration, increasing awareness of technologically advanced products, rising prevalence of hemophilia, and a large patient pool.

The increasing research on gene therapies and favorable outcomes are expected to drive market growth in the United States. On the other hand, Asia-Pacific is expected to experience significant growth during the forecast period. Factors such as increased per capita use of medications for factor VIII and IX deficiencies and early disease detection in countries like Japan, India, Indonesia, and Malaysia contribute to this growth.

Major companies operating in Global Haemophilia Treatment Market are:

  • Bayer AG
  • BioMarin Pharmaceutical, Inc.
  • CSL Behring LLC
  • Kedrion S.p.A
  • Novo Nordisk A/S      
  • Pfizer, Inc.
  • Octapharma AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Grifols S.A.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The growing number of hemophilic patients and the increasing prevalence of genetic abnormalities worldwide are key factors that positively impact the market. Moreover, the rising diagnosis rate of the disease and the growing adoption of prophylactic treatment for hemophilia present profitable growth opportunities for leading market players. Furthermore, government agencies in various countries are organizing extensive awareness campaigns to promote early diagnosis and appropriate screening procedures for neonates, thereby creating a positive market outlook. Additionally, substantial investments in research and development (R&D) activities are being made due to the limited availability of treatment options. Notably, industry leaders are focused on introducing advanced diagnostic tools and therapies to enhance the effectiveness and precision of hemophilia treatment, further contributing to a favorable market landscape. Additionally, significant investments are being made to expand the establishment of specialized hemophilia treatment centers (HTCs) globally, which is expected to drive market growth.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Haemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Haemophilia A, Haemophilia B, Haemophilia C), By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI therapy and Gene Therapy), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Haemophilia Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Haemophilia Treatment Market.



TechSci Research LLC

420 Lexington Avenue, Suite 300, New York, United States- 10170

Email: [email protected]

M: +13322586602

Relevant News